Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

News You Need to Know Today
FDA committee backs new COVID-19 vaccine despite heart damage concerns | New data on CV conditions & dementia
Friday, June 10, 2022
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

Today's News and Trends

FDA committee backs Novavax's COVID-19 vaccine despite heart damage concerns

The committee's approval comes days after the FDA shared details on a small number of trial participants who developed myocarditis or pericarditis after receiving the vaccine.  

READ MORE >
Novavax NVX-CoV2373 COVID-19 vaccine myocarditis
Share on Twitter Share on Facebook Share on Linkedin

FDA committee backs Novavax's COVID-19 vaccine despite heart damage concerns

Share on Twitter Share on Facebook Share on Linkedin
Novavax NVX-CoV2373 COVID-19 vaccine myocarditis
The committee's approval comes days after the FDA shared details on a small number of trial participants who developed myocarditis or pericarditis after receiving the vaccine.  
READ MORE >

Risk of dementia skyrockets when patients have more than 1 cardiovascular condition

“Many studies look at the risk of a single condition in relation to dementia, but health is more complex than that,” one researcher said.

READ MORE >
patient_exam_cardiology_covid_dr_cowan_beaumont.jpeg
Share on Twitter Share on Facebook Share on Linkedin

Risk of dementia skyrockets when patients have more than 1 cardiovascular condition

Share on Twitter Share on Facebook Share on Linkedin
patient_exam_cardiology_covid_dr_cowan_beaumont.jpeg
“Many studies look at the risk of a single condition in relation to dementia, but health is more complex than that,” one researcher said.
READ MORE >

Featured Articles

VIDEO: Creating an integrated heart team program in central Texas

Charles D. Fraser, Jr., MD, executive director of the new Institute for Cardiovascular Health in Austin, Texas, discusses the facility's new, state-of-the-art cardiology program.

READ MORE >
Charles D. Fraser, Jr., MD, executive director of the new Institute for Cardiovascular Health, a collaboration between Ascension Texas and the University of Texas at Austin, including its Dell Medical School. This new, state-of-the-art cardiology program fully integrates all the cardiac subspecialties to create a comprehensive heart team approach in treating patients.
Share on Twitter Share on Facebook Share on Linkedin

VIDEO: Creating an integrated heart team program in central Texas

Share on Twitter Share on Facebook Share on Linkedin
Charles D. Fraser, Jr., MD, executive director of the new Institute for Cardiovascular Health, a collaboration between Ascension Texas and the University of Texas at Austin, including its Dell Medical School. This new, state-of-the-art cardiology program fully integrates all the cardiac subspecialties to create a comprehensive heart team approach in treating patients.
Charles D. Fraser, Jr., MD, executive director of the new Institute for Cardiovascular Health in Austin, Texas, discusses the facility's new, state-of-the-art cardiology program.
READ MORE >

Links to all the SCAI 2022 late-breaking clinical research

The Society for Cardiovascular Angiography and Interventions (SCAI) has announced its late-breaking study presentations at its 2022 Scientific Sessions. 

READ MORE >
Simpsons Interventions, a California-based healthcare technology company, has received the FDA’s breakthrough device designation for its Acolyte Image Guided Crossing and Re-Entry Catheter System. SCAI released the list of its late-breaking clinical study trials at its 2022 annual meeting. #SCAI #SCAI22 #SCAI2022
Share on Twitter Share on Facebook Share on Linkedin

Links to all the SCAI 2022 late-breaking clinical research

Share on Twitter Share on Facebook Share on Linkedin
Simpsons Interventions, a California-based healthcare technology company, has received the FDA’s breakthrough device designation for its Acolyte Image Guided Crossing and Re-Entry Catheter System. SCAI released the list of its late-breaking clinical study trials at its 2022 annual meeting. #SCAI #SCAI22 #SCAI2022
The Society for Cardiovascular Angiography and Interventions (SCAI) has announced its late-breaking study presentations at its 2022 Scientific Sessions. 
READ MORE >

In Case You Missed It

FDA announces Class I recall of 4,800 imaging catheters due to risk of vascular injury

There have been five reported incidents so far, including one patient injury.

READ MORE >
Dragonfly OpStar Imaging Catheter FDA recall May 2022
Share on Twitter Share on Facebook Share on Linkedin

FDA announces Class I recall of 4,800 imaging catheters due to risk of vascular injury

Share on Twitter Share on Facebook Share on Linkedin
Dragonfly OpStar Imaging Catheter FDA recall May 2022
There have been five reported incidents so far, including one patient injury.
READ MORE >

Open AAA repair linked to better long-term outcomes than EVAR

However, the authors noted, 30-day survival is significantly higher after EVAR than open AAA repair.  

READ MORE >
Abdominal aortic aneurysm (AAA)
Share on Twitter Share on Facebook Share on Linkedin

Open AAA repair linked to better long-term outcomes than EVAR

Share on Twitter Share on Facebook Share on Linkedin
Abdominal aortic aneurysm (AAA)
However, the authors noted, 30-day survival is significantly higher after EVAR than open AAA repair.  
READ MORE >

In Other News

Healthcare CEOs urge Congress to act on gun violence

Among the CEOs who signed the letter are a handful of prominent healthcare leaders.

READ MORE >
Share on Twitter Share on Facebook Share on Linkedin

Healthcare CEOs urge Congress to act on gun violence

Share on Twitter Share on Facebook Share on Linkedin
Among the CEOs who signed the letter are a handful of prominent healthcare leaders.
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

TAVR for moderate aortic stenosis | BP drug recalled | Stroke prevention device fails | New Medicare cuts | CCTA-guided PCI
A new way to think about the heart health of women | GLP-1 drugs vs. metformin | Cannabis use may increase risk of CVD, stroke
New Medicare payment cuts | Telemedicine vs. in-person cardiology visits | FDA confirms Class I recall | Startup raises $160M
FDA approves transcatheter treatment for PVL | CCTA-guided PCI | Real-world RDN outcomes | J&J launches new IVL catheter
CCTA vs. IVUS for PCI guidance: Carlos Collet reviews the data | The real-world benefits of RDN | New TAVR tech falls short
TAVR Highlights: New data on treating moderate AS | CMS may expand coverage again | Is surgical backup still necessary?
GLP-1 drugs vs. metformin | BP drug recalled | The health risks of cannabis use | Energy drinks linked to heart issues
Newsletter archive
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
  • Press Releases
  • Submit Press Release
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
Design by Adaptive Theme